<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03070262</url>
  </required_header>
  <id_info>
    <org_study_id>CAEC</org_study_id>
    <nct_id>NCT03070262</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Caffeic Acid for Esophageal Cancer</brief_title>
  <acronym>CAEC</acronym>
  <official_title>Caffeic Acid for Advanced Esophageal Squamous Cell Cancer: A Randomized, Double-blind, and Multicenter Trial in Chinese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Henan University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Anyang Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>150th Hospital of PLA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital of Henan University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Caffeic acid can target inhibit GASC1 expression and GASC1 is confirmed to be a new oncogene
      in several cancers including esophageal cancer. This study aims to investigate the efficiency
      and safety of coffeic acid in chinese advanced esophageal squamous cell cancer (ESCC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: More than half of global esophageal cancer cases came from China.80 percentage
      patients were diagnosed with advanced disease and suffered from the poor outcome.With the
      development of target therapy among cancers,the overall survival and life quality of patients
      has been continuous improved recently.However,there had little reports focusing on esophageal
      cancer target therapy. Caffeic acid as an ordinary drug is used for thrombocytopenia when
      patient recieved chemotherapy. Newly studies shown caffeic acid can target inhibit GASC1
      expression, and GASC1 is confirmed to be a new oncogene in esophageal cancer.

      Aim: to investigate the efficiency and safety of caffeic acid in chinese advanced esophageal
      squamous cell cancer.

      Methods: 300 advanced ESCC patients will be randomized to two arms: CA group (recieving
      coffeic acid treatment) or placebo group.In CA group, patients will recieve coffeic acid
      treatment: 300mg, tid, po; in placebo group, the same shape placebo tablets will be
      deliveried to patients. 1 years follow-up for both groups patients.Patients in both arms can
      receive any other ways of anti cancer therapy in the same time.

      Primary endpoints: 3 months PFS; Second endpoints: 1 year OS
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3 months PFS</measure>
    <time_frame>3 months</time_frame>
    <description>The percentage of 3 months progression-free survival after random allocation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1 year OS</measure>
    <time_frame>1 year</time_frame>
    <description>The percentage of 1 year overall survival after random allocation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Esophagus Cancer</condition>
  <arm_group>
    <arm_group_label>CA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>caffeic acid (300mg, tid, po) continue given until progression of disease or death, or patients are unable to bear the side effects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>the same shape placebo tablets continue given until progression of disease or death, or patients are unable to bear the side effects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CA</intervention_name>
    <description>caffeic acid, 300mg, tid, po</description>
    <arm_group_label>CA group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo group</intervention_name>
    <description>placebo tablet, 3 tablets, tid, po</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chinese

          -  esophageal squamous cell cancer

          -  stage IV or disease recurrence

          -  chemotherapy, or radiotherapy, or palliative care is going on

        Exclusion Criteria:

          -  PS: ≥ 3

          -  severe hepatic and renal dysfunction

          -  hypercoagulability

          -  thrombocytosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shegan Gao, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>The Clinical Medical College, The First Affiliated Hospital of Henan Science and Technology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Clinical Medical College, The First Affiliated Hospital of Henan University of Science and Technology</name>
      <address>
        <city>Luoyang</city>
        <state>Henan</state>
        <zip>471003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Li S, Zhang W, Yang Y, Ma T, Guo J, Wang S, Yu W, Kong L. Discovery of oral-available resveratrol-caffeic acid based hybrids inhibiting acetylated and phosphorylated STAT3 protein. Eur J Med Chem. 2016 Nov 29;124:1006-1018. doi: 10.1016/j.ejmech.2016.10.028. Epub 2016 Oct 15.</citation>
    <PMID>27783972</PMID>
  </reference>
  <results_reference>
    <citation>Pedersen MT, Kooistra SM, Radzisheuskaya A, Laugesen A, Johansen JV, Hayward DG, Nilsson J, Agger K, Helin K. Continual removal of H3K9 promoter methylation by Jmjd2 demethylases is vital for ESC self-renewal and early development. EMBO J. 2016 Jul 15;35(14):1550-64. doi: 10.15252/embj.201593317. Epub 2016 Jun 6.</citation>
    <PMID>27266524</PMID>
  </results_reference>
  <results_reference>
    <citation>Movassaghian S, Xie Y, Hildebrandt C, Rosati R, Li Y, Kim NH, Conti DS, da Rocha SR, Yang ZQ, Merkel OM. Post-Transcriptional Regulation of the GASC1 Oncogene with Active Tumor-Targeted siRNA-Nanoparticles. Mol Pharm. 2016 Aug 1;13(8):2605-21. doi: 10.1021/acs.molpharmaceut.5b00948. Epub 2016 Jun 27.</citation>
    <PMID>27223606</PMID>
  </results_reference>
  <results_reference>
    <citation>Sudo G, Kagawa T, Kokubu Y, Inazawa J, Taga T. Increase in GFAP-positive astrocytes in histone demethylase GASC1/KDM4C/JMJD2C hypomorphic mutant mice. Genes Cells. 2016 Mar;21(3):218-25. doi: 10.1111/gtc.12331. Epub 2016 Jan 25.</citation>
    <PMID>26805559</PMID>
  </results_reference>
  <results_reference>
    <citation>Ye Q, Holowatyj A, Wu J, Liu H, Zhang L, Suzuki T, Yang ZQ. Genetic alterations of KDM4 subfamily and therapeutic effect of novel demethylase inhibitor in breast cancer. Am J Cancer Res. 2015 Mar 15;5(4):1519-30. eCollection 2015.</citation>
    <PMID>26101715</PMID>
  </results_reference>
  <results_reference>
    <citation>Ozaki Y, Fujiwara K, Ikeda M, Ozaki T, Terui T, Soma M, Inazawa J, Nagase H. The oncogenic role of GASC1 in chemically induced mouse skin cancer. Mamm Genome. 2015 Dec;26(11-12):591-7. doi: 10.1007/s00335-015-9592-9. Epub 2015 Aug 7.</citation>
    <PMID>26248577</PMID>
  </results_reference>
  <results_reference>
    <citation>Sun LL, Wu JY, Wu ZY, Shen JH, Xu XE, Chen B, Wang SH, Li EM, Xu LY. A three-gene signature and clinical outcome in esophageal squamous cell carcinoma. Int J Cancer. 2015 Mar 15;136(6):E569-77. doi: 10.1002/ijc.29211. Epub 2014 Sep 24.</citation>
    <PMID>25220908</PMID>
  </results_reference>
  <results_reference>
    <citation>Uimonen K, Merikallio H, Pääkkö P, Harju T, Mannermaa A, Palvimo J, Kosma VM, Soini Y. GASC1 expression in lung carcinoma is associated with smoking and prognosis of squamous cell carcinoma. Histol Histopathol. 2014 Jun;29(6):797-804. doi: 10.14670/HH-29.797. Epub 2013 Dec 27.</citation>
    <PMID>24371038</PMID>
  </results_reference>
  <results_reference>
    <citation>Sun LL, Holowatyj A, Xu XE, Wu JY, Wu ZY, Shen JH, Wang SH, Li EM, Yang ZQ, Xu LY. Histone demethylase GASC1, a potential prognostic and predictive marker in esophageal squamous cell carcinoma. Am J Cancer Res. 2013 Nov 1;3(5):509-17. eCollection 2013.</citation>
    <PMID>24224128</PMID>
  </results_reference>
  <results_reference>
    <citation>Berdel B, Nieminen K, Soini Y, Tengström M, Malinen M, Kosma VM, Palvimo JJ, Mannermaa A. Histone demethylase GASC1--a potential prognostic and predictive marker in invasive breast cancer. BMC Cancer. 2012 Nov 14;12:516. doi: 10.1186/1471-2407-12-516.</citation>
    <PMID>23148692</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu G, Bollig-Fischer A, Kreike B, van de Vijver MJ, Abrams J, Ethier SP, Yang ZQ. Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. Oncogene. 2009 Dec 17;28(50):4491-500. doi: 10.1038/onc.2009.297. Epub 2009 Sep 28.</citation>
    <PMID>19784073</PMID>
  </results_reference>
  <results_reference>
    <citation>Yuan X, Kong J, Ma Z, Li N, Jia R, Liu Y, Zhou F, Zhan Q, Liu G, Gao S. KDM4C, a H3K9me3 Histone Demethylase, is Involved in the Maintenance of Human ESCC-Initiating Cells by Epigenetically Enhancing SOX2 Expression. Neoplasia. 2016 Oct;18(10):594-609. doi: 10.1016/j.neo.2016.08.005. Epub 2016 Sep 19. Erratum in: Neoplasia. 2016 Dec;18(12 ):810.</citation>
    <PMID>27742014</PMID>
  </results_reference>
  <results_reference>
    <citation>Tyszka-Czochara M, Konieczny P, Majka M. Caffeic Acid Expands Anti-Tumor Effect of Metformin in Human Metastatic Cervical Carcinoma HTB-34 Cells: Implications of AMPK Activation and Impairment of Fatty Acids De Novo Biosynthesis. Int J Mol Sci. 2017 Feb 21;18(2). pii: E462. doi: 10.3390/ijms18020462.</citation>
    <PMID>28230778</PMID>
  </results_reference>
  <results_reference>
    <citation>Bonuccelli G, De Francesco EM, de Boer R, Tanowitz HB, Lisanti MP. NADH autofluorescence, a new metabolic biomarker for cancer stem cells: Identification of Vitamin C and CAPE as natural products targeting &quot;stemness&quot;. Oncotarget. 2017 Mar 28;8(13):20667-20678. doi: 10.18632/oncotarget.15400.</citation>
    <PMID>28223550</PMID>
  </results_reference>
  <results_reference>
    <citation>Chung LC, Chiang KC, Feng TH, Chang KS, Chuang ST, Chen YJ, Tsui KH, Lee JC, Juang HH. Caffeic acid phenethyl ester upregulates N-myc downstream regulated gene 1 via ERK pathway to inhibit human oral cancer cell growth in vitro and in vivo. Mol Nutr Food Res. 2017 Sep;61(9). doi: 10.1002/mnfr.201600842. Epub 2017 Mar 20.</citation>
    <PMID>28181403</PMID>
  </results_reference>
  <results_reference>
    <citation>Dziedzic A, Kubina R, Kabała-Dzik A, Tanasiewicz M. Induction of Cell Cycle Arrest and Apoptotic Response of Head and Neck Squamous Carcinoma Cells (Detroit 562) by Caffeic Acid and Caffeic Acid Phenethyl Ester Derivative. Evid Based Complement Alternat Med. 2017;2017:6793456. doi: 10.1155/2017/6793456. Epub 2017 Jan 12.</citation>
    <PMID>28167973</PMID>
  </results_reference>
  <results_reference>
    <citation>Sirota R, Gibson D, Kohen R. The timing of caffeic acid treatment with cisplatin determines sensitization or resistance of ovarian carcinoma cell lines. Redox Biol. 2017 Apr;11:170-175. doi: 10.1016/j.redox.2016.12.006. Epub 2016 Dec 7.</citation>
    <PMID>27951496</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2017</study_first_submitted>
  <study_first_submitted_qc>February 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2017</study_first_posted>
  <last_update_submitted>February 28, 2017</last_update_submitted>
  <last_update_submitted_qc>February 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>esophageal cancer</keyword>
  <keyword>caffeic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caffeic acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

